What is Immunic Inc Annual Net Profit?

Immunic Inc Annual Net Profit rose 27.16% in the last year to $93.61 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is Immunic Inc Price to Earning Ratio?

Immunic Inc Price to Earning Ratio is -1.09, which is negative.

What is Immunic Inc Stock Price?

Immunic Inc Stock Price fell 11.36% and underperformed its sector by 21.26% in the past year.

What is Immunic Inc Quarterly Net profit?

Immunic Inc Quarterly Net profit fell 7.02% YoY to $24.37 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is Immunic Inc Debt to Equity Ratio?

Immunic Inc Debt to Equity Ratio of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Immunic Inc Return on Equity(ROE)?

Immunic Inc Return on Equity(ROE) for the last financial year was -131.28%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Immunic Inc Mutual Fund Holding?

Immunic Inc Mutual Fund Holding increased by 0.6% in the last quarter to 12.41.

What is Immunic Inc Promoter Share Holding?

Immunic Inc Promoter Share Holding stayed the same in the most recent quarter at 5.21%.

What is Immunic Inc Institutional Holding?

Immunic Inc Institutional Holding decreased by 5.3% in the last quarter to 59.75.

How is the Immunic Inc today?

The Immunic Inc today is trading in the green, up by 1.74% at 1.17.

How has Immunic Inc performed historically?

The Immunic Inc is currently trading up 1.74% on an intraday basis in the past week the index rose 1.74%. The index has been up 12.50% in the past quarter and fell -11.36% in the past year. You can view this in the overview section.

Immunic Inc XNAS: IMUX

Immunic Inc Live Share Price Today, Share Analysis and Chart

Name: Immunic Inc: Is Infosys Ltd. worth buying?
Item: Immunic Inc
Rating: 1.20775
Author: Trendlyne DVM scores

Download real time

1.17 0.02 (1.74%)

44.55% Fall from 52W High

539.8K XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Board Meeting

The latest board meeting for Immunic Inc took place on 24 Mar 2025, for the purpose of Immunic Inc Annual Report for 2024 See details

Immunic Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	105.4
PE TTM Negative PE TTM Unavailable in chosen country	-1.1
Price to Book Below industry Median Unavailable in chosen country	2.6
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	59.7
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-7
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	24.6
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	5.2
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-131.3
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-102.8

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

6.5 / 100

Technically Neutral

41.8 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Immunic Inc Stock Price Analysis

Day Price Range 1.7% 1 Day return Unavailable in chosen country	1.2 (LTP) 1.21.2 LowHigh
Week Price Range 1.7% 1 Week return Unavailable in chosen country	1.2 (LTP) 1.11.2 LowHigh
Month Price Range -7.9% 1 Month return Unavailable in chosen country	1.2 (LTP) 11.3 LowHigh
52 Week Price Range -11.4% 1 Year return Unavailable in chosen country	1.2 (LTP) 0.92.1 LowHigh

View full Share Price History

Immunic Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Immunic Inc Stock Analysis

Immunic Inc stock analysis with key metrics, changes, and trends.

Immunic Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$93.61 M	27.16%	positive	Annual Net Profit rose 27.16% in the last year to $93.61 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-1.09	-	negative	Price to Earning Ratio is -1.09, which is negative.
Stock Price	$1.17	-11.36%	negative	Stock Price fell 11.36% and underperformed its sector by 21.26% in the past year.
Quarterly Net profit	$24.37 M	7.02%	negative	Quarterly Net profit fell 7.02% YoY to $24.37 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Debt to Equity Ratio	0.05	-	positive	Debt to Equity Ratio of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-131.28 %	-131.28%	negative	Return on Equity(ROE) for the last financial year was -131.28%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	12.41 %	0.6%	positive	Mutual Fund Holding increased by 0.6% in the last quarter to 12.41.
Promoter Share Holding	5.21 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 5.21%.
Institutional Holding	59.75 %	-5.3%	negative	Institutional Holding decreased by 5.3% in the last quarter to 59.75.

VIEW LESS

Loading data..

Immunic Inc - Company Profile

What does Immunic Inc do?

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic Inc Management structure

All Gross Remunerations are in USD

Dr. Daniel Vitt, PhD

Director and Chief Executive Officer

2024

Gross Remuneration

Year

Mr. Werner Gladdines

Chief Development Officer

2024

Gross Remuneration

Year

Mr. Jason Tardio, M.B.A.

Chief Operating Officer and President

2024

Gross Remuneration

Year

Immunic Inc Board of directors

All Gross Remunerations are in USD

Dr. Daniel Vitt, PhD

Director and Chief Executive Officer

2024

Gross Remuneration

Year

Ms. Simona Skerjanec, M.B.A.

Director

2024

Gross Remuneration

Year

Immunic Inc Live Share Price Today, Share Analysis and Chart

44.55% Fall from 52W High

Immunic Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Immunic Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Immunic Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Immunic Inc Stock Analysis

Immunic Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 27.16% in the last year to $93.61 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -1.09, which is negative.

Stock Price fell 11.36% and underperformed its sector by 21.26% in the past year.

Quarterly Net profit fell 7.02% YoY to $24.37 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Debt to Equity Ratio of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -131.28%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.6% in the last quarter to 12.41.

Promoter Share Holding stayed the same in the most recent quarter at 5.21%.

Institutional Holding decreased by 5.3% in the last quarter to 59.75.

Immunic Inc - Company Profile

What does Immunic Inc do?

Immunic Inc Management structure

Dr. Daniel Vitt, PhD

Director and Chief Executive Officer

Mr. Werner Gladdines

Chief Development Officer

Mr. Jason Tardio, M.B.A.

Chief Operating Officer and President

Immunic Inc Board of directors

Dr. Daniel Vitt, PhD

Director and Chief Executive Officer

Ms. Simona Skerjanec, M.B.A.

Director

Immunic Inc FAQ

How is Immunic Inc today?

Immunic Inc today is trading in the green, and is up by 1.74% at 1.17.

How has Immunic Inc performed historically?

Immunic Inc is currently trading up 1.74% on an intraday basis. In the past week the stock rose 1.74%. stock has been up 12.50% in the past quarter and fell -11.36% in the past year. You can view this in the overview section.